$SLDP

Solid Power, Inc. Q2 2026 Earnings Call Summary

Solid Power reported Q2 2026 revenue of -$300,000 due to a $1.2 million non-cash reversal tied to updated SK On R&D license milestone assumptions. The company said it completed major equipment installation for a 45-metric-ton continuous pilot line, with output expected in Q1 2027, and is advancing a South Korea electrolyte JV and ISO 9001 certification. It reported $419.3 million liquidity and zero debt.

Original reporting
Published Aug 7, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 12:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Solid Power, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$SLDPBullishMed
01

Why it matters

The most tradable elements are the updated, time-stamped execution milestones (Q3 2026 acceptance testing, Q4 2026 plant validation/start-up, Q1 2027 first output) and the claim that SK On installation milestones were completed, triggering a milestone payment. These details can shift near-term probability of commercialization and partner confidence.

02

Market read

Execution updates and partner milestone progress provide a clearer path to 2027 output, but the near-term financials include non-cash revenue reversal noise.

03

What to watch

The Q2 revenue figure is distorted by a non-cash reversal tied to SK On R&D license assumptions, so traders should separate accounting noise from operational traction.

Relevance 7/10Novelty 6/10Timing: ahead of Q3 2026 equipment acceptance testing and year-end 2026 JV/ISO milestones

Background

Solid Power’s Q2 2026 call summary focuses on electrolyte material performance improvements, continuous manufacturing pilot-line commissioning, and commercialization planning with SK On plus a potential South Korea joint venture.

Company-level read

Ticker impact

$SLDPBullishMedium confidence
Context

Solid Power reports Q2 progress on its continuous electrolyte pilot line, including SK On milestone-triggered installation and Q1 2027 first output expectations.

Expected impact

Moderate upside bias into Q3-Q4 2026 as commissioning and ISO/JV milestones de-risk commercialization, with volatility around JV definitiveness and equipment acceptance testing.

Evidence & confidence

The article discloses multiple time-bound operational milestones (equipment commissioning, acceptance testing, plant validation, first output) plus a triggered milestone payment from SK On, which can change probability-weighted commercialization timelines.

Market effects

All-solid-state battery supply-chain de-risking signals may support sentiment toward electrolyte/materials developers and downstream cell makers.

South Korea JV discussions highlight potential acceleration of regional all-solid-state battery commercialization timelines.

If the South Korea electrolyte JV advances, it could affect global ASB supply availability and cost curves over 2027 onward.

Counterpoint

Milestone-driven progress may not translate into revenue until sustained commercial output; JV timing and acceptance testing could slip, keeping valuation dependent on execution rather than cash generation.

Key entities

  • Solid Power, Inc.

    Electrolyte materials and continuous manufacturing pilot-line execution, with SK On milestone completion and planned South Korea JV announcement by end of 2026.

  • SK On

    Completed Line Installation Agreement milestone with Solid Power, triggering a milestone payment; ongoing collaboration via R&D license assumptions.

  • Samsung SDI

    Joint Evaluation Agreements for electrolyte materials performance and lot-to-lot consistency improvements.

  • BMW

    Joint Evaluation Agreements supporting electrolyte performance and particle size requirements.

Related articles

$SLDPMed

SOLID POWER REPORTS SECOND QUARTER 2026 RESULTS

Solid Power, Inc. (SLDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SOLID POWER REPORTS SECOND QUARTER 2026 RESULTS LOUISVILLE, Colo., August 4, 2026 – Solid Power, Inc. (Nasdaq: SLDP), a leading developer of solid-state battery technology, today announced its operational and financial results for the second quarter and first half of

$QSMedAI 8/10

QuantumScape Sinks 14%, Solid Power and SES AI Fall as Solid

QuantumScape (NYSE:QS) fell about 14% to $5.03 after its Q2 2026 results, despite a narrower-than-expected net loss of ~$98 million ($0.16/share vs est. $0.1781). It reaffirmed 2026 adjusted EBITDA loss guidance of $250 million to $275 million and trimmed capex to $27 million to $37 million. Honda partnership and defense/AI milestones did not prevent selling; Solid Power (NASDAQ:SLDP) and SES AI (NYSE:SES) also dropped.

$GSKMedAI 8/10

Alteogen ALT-B4-based ‘Jemperli SC’ heads into clinical trials, GSK signals November start

GSK is advancing a subcutaneous version of its drug Jemperli, using Alteogen's ALT-B4, into clinical trials starting November. The Phase 1b/3 trial will enroll 380 patients with advanced endometrial cancer. GSK licensed ALT-B4 from Alteogen in January 2026 for USD 285 million in potential milestones. Jemperli generated GBP 861 million in 2025 sales. Alteogen's ALT-B4 is also used in MSD's Keytruda SC, which generated USD 463 million in Q2 2026.

$MRKMedAI 8/10

Merck eye drug matches anti-VEGF in DME trial with safety caveats

Merck (MRK) reported one-year results from its BRUNELLO trial for remigromig, an investigational drug for diabetic macular edema (DME). Both doses met the primary endpoint, showing non-inferiority to ranibizumab in visual acuity improvement. However, adverse events related to proliferative diabetic retinopathy were more frequent with remigromig. Merck plans to discuss results with regulators and is conducting further analyses.